Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Opyl Ltd. ( (AU:OPL) ) has provided an update.
Opyl Limited has appointed Matt Hallam as Chief Revenue Officer to enhance the commercial growth of its core product, TrialKey.ai, in the biopharmaceutical and clinical research sectors. Hallam’s extensive experience in digital health and clinical trials, along with his leadership roles in major healthcare companies, will be pivotal in establishing TrialKey.ai as a leader in AI-driven clinical trial design and feasibility, driving sustainable revenue growth and expanding market presence.
More about Opyl Ltd.
Opyl Limited is an AI company focused on transforming clinical trials and medical research through data and technology. The company is committed to innovation and strategic growth, positioning itself as a leader in the future of healthcare solutions.
Average Trading Volume: 347,687
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.93M
Learn more about OPL stock on TipRanks’ Stock Analysis page.